Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis
American Journal of Hypertension · 01.07.2026 · 39 (7) · 911-920
DOI: 10.1093/ajh/hpaf246 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Hypertension, online erschienen am 22.12.2025. Verfasst von Vicente Morales Ribeiro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Southern Santa Catarina, Palhoça, Brazil. Hauptthemen laut MEDLINE: Hypertension, Blood Pressure, Antihypertensive Agents, Benzazepines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
The efficacy and safety of lorundrostat, a selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension remain unclear. This meta-analysis aimed to evaluate its effects on blood pressure and risk of hyperkalemia.
Methods
PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were systematically searched through July 2025 for randomized controlled trials comparing lorundrostat with placebo. Pooled mean differences (MD) and risk ratios (RR) with 95% CIs were estimated using a random-effects model with the Restricted Maximum Likelihood estimator. Trial sequential analysis (TSA) was conducted to assess the conclusiveness of safety evidence.
Results
Three RCTs including 1060 patients were identified. Lorundrostat significantly reduced systolic blood pressure at 50 mg (MD, −9.08 mmHg; 95% CI, −13.14 to −5.03) and 100 mg (MD, −11.41 mmHg; 95% CI, −15.97 to −6.85), and diastolic blood pressure at 50 mg (MD, −3.48 mmHg; 95% CI, −5.98 to −0.98). However, lorundrostat increased the risk of hyperkalemia at 50 mg (RR, 6.56; 95% CI, 1.53-28.12; NNH = 71) and 100 mg (RR, 10.37; 95% CI, 2.44-44.03; NNH = 42). TSA confirmed hyperkalemia at 100 mg as the only conclusive harm signal, while other safety outcomes remained inconclusive.
Conclusions
Lorundrostat effectively lowered blood pressure but increased dose-dependent risk of hyperkalemia. These findings support its potential as a novel therapy for uncontrolled hypertension, while emphasizing the need for longer-term cardiovascular outcome trials and direct comparisons with mineralocorticoid receptor antagonists concerning efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Southern Santa Catarina, Palhoça, Brazil.
- Albert Einstein Israeli Institute of Education and Research (IIEP), Hospital Israelita Albert Einstein, Goiânia, Brazil.
- Department of Internal Medicine, Serra Gaúcha University Center, Caxias do Sul, Brazil.
- Department of Internal Medicine, Federal University of Paraná, Curitiba, Brazil.
- Department of Internal Medicine, Redentor University Center, Itaperuna, Brazil.
- Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
ORCID-Profile: Vicente Morales Ribeiro, Douglas Nunes Cavalcante, Hermes Estevam Torega Celkevicius, Giovanna Cristina Gonçalves Camacho, Henrique Alexsander Ferreira Neves, Kevlin de Souza, Rafael Henkes Machado, Lucca Moreira Lopes, Webster Donaldy, Luiz Aparecido Bortolotto
Zitieren
APA
Ribeiro, V. M., Cavalcante, D. N., Celkevicius, H. E. T., Camacho, G. C. G., Neves, H. A. F., de Souza, K., Machado, R. H., Lopes, L. M., Donaldy, W., Bortolotto, L. A., & Schneider, J. C. (2026). Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. American Journal of Hypertension, 39(7), 911-920. https://doi.org/10.1093/ajh/hpaf246
Vancouver
Ribeiro VM, Cavalcante DN, Celkevicius HET, Camacho GCG, Neves HAF, de Souza K, et al. Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. American Journal of Hypertension. 2026;39(7):911-920. doi:10.1093/ajh/hpaf246
BibTeX
@article{Ribeiro2026,
author = {Ribeiro, Vicente Morales and Cavalcante, Douglas Nunes and Celkevicius, Hermes Estevam Torega and Camacho, Giovanna Cristina Gonçalves and Neves, Henrique Alexsander Ferreira and de Souza, Kevlin and Machado, Rafael Henkes and Lopes, Lucca Moreira and Donaldy, Webster and Bortolotto, Luiz Aparecido and Schneider, Jamil Cherem},
title = {Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis},
journal = {American Journal of Hypertension},
year = {2026},
volume = {39},
number = {7},
pages = {911--920},
doi = {10.1093/ajh/hpaf246}
}
EUVIMED